Clinimark

23/11/2021

BBMRI-ERIC is looking for a Research & Outreach Assistent. Details are online

Take a look at the current openings at BBMRI-ERIC

25/05/2021

Looking for new challenges? Join our team :-) More information

Job vacancies at BBMRI-ERIC, the European research infrastructure for biobanking, based in Graz, Austria. Apply for jobs in the biomedical sciences in Graz.

23/03/2021

Virtual Summer School in Personalised Medicine.
June 14-18 2021
DON'T MISS IT!!!!

More information online

We are very happy to announce the Summer School in , held virtually on June 14-18, 2021! Led by our partners INFARMED,...

16/02/2021

Quantitative information at the proteome level aids in revealing the roles of proteins in biological, physiological and pathological processes. The most widely used strategies in mass spectrometry-based proteome-wide quantitative approaches, other than label-free quantification, are based on stable isotope labeling, which allows us to analyse multiple samples simultaneously in a single LC-MS run.

To reduce the complexity of MS2 spectra of IPTL methods and to further improve multiplexing capacity, researcher of the consortium propose a novel labeling approach that relies on a collision-induced dissociation (CID)-cleavable isobaric Ac-IPG tag. In this method, quantitative information is concealed in the Ac-IPG tag, which is located on the ε-amino group of the C-terminal Lys residue of LysC peptides and revealed upon tandem MS in the form of y-ion clusters containing different numbers of .
Read more online https://pubs.acs.org/doi/abs/10.1021/acs.jproteome.0c00371

Visit our website https://clinimark.eu/ for more information on analytical and clinical validation of , and the COST Action network CliniMARK.

11/02/2021

Quantifying proteins based on peptide-coupled reporter ions is a multiplexed quantitative strategy in proteomics that alleviates the problem of ratio distortion caused by peptide cofragmentation, as commonly observed in other reporter-ion-based approaches, such as TMT and iTRAQ. Data-independent acquisition (DIA) is an attractive alternative to data-dependent acquisition (DDA) due to its better reproducibility.

To establish a new peptide-coupled reporter-ion-based tag that avoids ratio distortion in DDA and improves the throughput of DIA-based methods without sacrificing the data acquisition rate, researcher of the consortium propose a novel isobaric Ac-AG tag, which conceals quantitative information in isobarically labeled peptides and reveals it upon tandem MS in the form of peptide-coupled reporter ions. Read more about the results and discussions online https://pubs.acs.org/doi/10.1021/acs.analchem.0c03858

Visit our website https://clinimark.eu/ for more information on analytical and clinical validation of , and the COST Action network CliniMARK.

09/02/2021

Being the most common and the most aggressive subtype among renal cancers, clear cell renal cell carcinoma (ccRCC) accounts for most RCC fatal outcomes. Such outcomes probably arise from significant intra-tumor and inter-tumor genetic diversity of ccRCC, revealed in recent genomic studies. Indeed, among genetic factors that contribute to RCC risk, the most investigated is mutation of VHL gene, underlying the abnormal accumulation of hypoxia-inducible factor α (HIFα) proteins in normoxia.

Researcher of the consortium investigated the prognostic significance of GSTO1 (rs4925) and GSTO2 (rs156697 and rs2297235) polymorphisms in clear cell renal cell carcinoma (ccRCC) patients. Read all about the study online https://www.mdpi.com/2072-6694/11/12/2038

Visit our website https://clinimark.eu/ for more information on analytical and clinical validation of , and the COST Action network CliniMARK.

04/02/2021

(RCC) represents a group of histologically similar neoplasms with significant intratumor and intertumor genetic heterogeneity. Recognized factors for RCC development include smoking, hypertension, obesity, as well as von Hippel–Lindau (VHL) disease. Inactivation of VHL, deregulated nuclear factor (erythroid‐derived 2)‐like 2 (Nrf2) pathway, and altered , together with changes in (GST) profile, are considered as important contributing factors in RCC development and progression.

Read more about the GST genotypes and what role they may play as risk modifiers https://iubmb.onlinelibrary.wiley.com/doi/abs/10.1002/biof.1560

Visit our website https://clinimark.eu/ for more information on analytical and clinical validation of , and the COST Action network CliniMARK.

02/02/2021

For more than a decade, it has been suggested that a complex interplay between and chronic inflammation represents one of the underlying mechanisms of gradual cardiac depression in (HF). Oxidative stress in HF is believed to be a consequence of increased circulating neurohormones and hemodynamic disorder, as well as inflammation and decreased oxygen delivery.

Having all that in mind, Researcher of the consortium conducted a pilot case-control study consisting of patients with HF due to coronary artery disease ( ) or idiopathic dilated cardiomyopathy ( ) in order to compare the distribution of common GST genotypes and the differential risk effect between these two entities.
Read all about this study online https://www.hindawi.com/journals/dm/2019/6984845/

Visit our website https://clinimark.eu/ for more information on analytical and clinical validation of , and the COST Action network CliniMARK.

28/01/2021

is a dangerous pregnancy condition affecting both the mother and offspring. It is a multifactorial disease with poorly understood pathogenesis, lacking effective treatments. Maternal immune response, inflammation and oxidative stress leading to endothelial dysfunction are the most prominent pathogenic processes implicated in preeclampsia development.

With this review https://link.springer.com/article/10.1007/s11906-020-1034-8 , researcher of the consortium give a detailed overview of the therapeutic applications and mechanisms of mesenchymal stem/stromal cells (MSCs) as a potential new treatment for preeclampsia.

Visit our website https://clinimark.eu/ for more information on analytical and clinical validation of , and the COST Action network CliniMARK.

26/01/2021

Increased is a hallmark of end-stage renal disease. Hemodialysis (HD) patients lacking glutathione transferase M1 (GSTM1) enzyme activity exhibit enhanced oxidative DNA damage and higher mortality rate than those with active GSTM1 enzyme.

Researcher of the CliniMARK consortium were conducting study where they used the vitamin E-bonded membranes ( ) in patients with homozygous GSTM1 gene deletion, and aimed to determine the effect of VEM on oxidative and inflammatory status in HD patients with homozygous GSTM1 gene deletion.
Read more about this study online https://pubmed.ncbi.nlm.nih.gov/32471186/

Visit our website https://clinimark.eu/ for more information on analytical and clinical validation of , and the COST Action network .

21/01/2021

Glutathione-S transferases (GSTs) are xenobiotic-conjugation enzymes involved in the detoxification process of heterocyclic aromatic amines and polycyclic aromatic hydrocarbons, widely recognized risk factors of (CRC) development. Polymorphism in GSTs often leads to alteration or complete lack of enzyme activity, which might have an effect on CRC .

Researcher of the CliniMARK consortium were investigating in a study GST gene variants as risk factors in patients with CRC. Read all about the methods and conclusion online https://pubmed.ncbi.nlm.nih.gov/30694518/

Visit our website https://clinimark.eu/ for more information on analytical and clinical validation of , and the COST Action network .

19/01/2021

Disturbed redox homeostasis represents a hallmark of cancer phenotypes, affecting cellular metabolism and redox signaling. Since reactive oxygen and nitrogen species (ROS/RNS) are involved in regulation of proliferation and apoptosis, they may play a double-faced role in cancer, entailing protumorigenic and tumor-suppressing effects in early and later stages, respectively.

Read all about "The Double-Faced Role of Nitric Oxide and Reactive Oxygen Species in Solid Tumors" (authors: S. Mijatović, et al) online https://pubmed.ncbi.nlm.nih.gov/32365852/

Visit our website https://clinimark.eu/ for more information on analytical and clinical validation of , and the COST Action network .